Aerpio Therapeutics shares sink more than 70 percent following top-line results from TIME-2b trial for moderate to severe non-proliferative diabetic retinopathy.

Aerpio Therapeutics shares sink more than 70 percent following top-line results from TIME-2b trial for moderate to severe non-proliferative diabetic retinopathy.

Aerpio Therapeutics announced top-line results from the TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy (NPDR)....

Pin It on Pinterest